■ MediPrint Ophthalmics has begun the SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This SIGHT-2 clinical program is designed to assess dose optimization. SIGHT-1 validated the company’s process and bimatoprost-releasing contact lenses for treating patients with mild to moderate glaucoma and ocular hypertension.

“This is a key milestone in MediPrint’s plan to provide a necessary ocular treatment option for millions of contact lens wearing patients,” said Praful Doshi, founder, chairman, and interim CEO in a news release. “Eye care professionals and glaucoma patients alike are eagerly seeking an alternative to administering ophthalmic drops daily and our weekly medicated contact lens will fulfill that need. We expect to finalize our dose by the first half of 2023 as we continue progressing on our path toward FDA submission.”